BCM Systems Onco-Immunology Laboratory

Systems Immunology
Spatial Biology
Single-Cell Multi-Omics
Proteogenomics & Immunopeptidomics
David J. Sugarbaker Division of Thoracic Surgery

[Cancer Cell @Cancer_Cell]

Multimodal spatial-omics reveal co-evolution of alveolar progenitors and proinflammatory niches in progression of lung precursor lesions https://t.co/N3FJGmSQF5

[Anirban Maitra @Aiims1742]

New @NatureMedicine paper from @bcmhouston
Autologous multiantigen-targeted T cell therapy for #PancreaticCancer: a phase 1/2 trial
https://t.co/7CXUAiTHfB
Hard to conclude too much beyond feasibility & safety given very heterogeneous population & concurrent chemotherapy

[Cancer Cell @Cancer_Cell]

Online Now: Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications https://t.co/xUr6yePSbV

[Cell @CellCellPress]

And improvements for personalized cancer vaccines with stronger CD4+ and CD8+ responses.
https://t.co/MurulJHrRS

[Cancer Cell @Cancer_Cell]

KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer https://t.co/MduSlA1kIo

[Diego A. Díaz-García @diegoadiazg]

🫁 Tumour–microenvironment crosstalk in #NSCLC drives resistance, metastasis, and outcomes.

Understanding spatial niches, inflammation, and immune evasion can reshape treatment strategies.

📖 @NatRevClinOncol
👉 https://t.co/VFjfHbOF9y

#CánCare #immunotherapy #biomarkers #lcsm

[The Journal of Immunology @J_Immunol]

This #BriefReview focuses on interferon (IFN) production in the thymus and its effects on thymic antigen presenting cells and developing thymocytes examining the importance of T-cell tolerance to IFN and interferon-stimulated proteins. Read more: https://t.co/JO4mpmXqJ7.

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC review: Tumor organoids in immunotherapy: from disease modeling to translational research https://t.co/BWS7PDGggJ

[BCM_Surgery @BCM_Surgery]

Today, we honor the enduring legacy of Dr. Michael E. DeBakey, a visionary surgeon, educator and medical pioneer whose groundbreaking work transformed cardiovascular surgery. Dr. DeBakey died on this day in 2008 at the age of 99, leaving behind a legacy that continues to shape modern medicine.

His innovations in surgical techniques and medical devices revolutionized heart and vascular care. His dedication to advancing medical education, research and patient care laid the foundation for generations of surgeons and continues to inspire medical professionals worldwide.

We celebrate his remarkable contributions and remain committed to carrying forward his legacy of excellence, innovation and service.

#DeBakey #BCMSurgery

[BCM Systems Onco-Immunology Laboratory @BCM_SOIL]

Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma https://t.co/PKLLV7JZcS. @CCR_AACR, @BCM_SOIL, @BCM_Surgery, @bcmhouston. #mesothelioma #Immunotherapy

[The Lancet @TheLancet]

🗨️ “Vaccines have done more to improve public health than any other medical intervention.”

A Viewpoint focuses on cancer vaccines and the future of immunotherapy—analysing trials, different vaccine approaches, and how the next generation of cancer vaccines can help improve patient outcomes and quality of life. https://t.co/5VXTVKx4Jd

[BCM_Surgery @BCM_Surgery]

This week we launched our “How To Workshop Series” with a session on understanding the grant review process, crafting specific aims, and developing a competitive research plan.

Featuring: Livia Eberlin, Ravi Ghanta, Thomas Milner, Tamer Mohamed, Hyun-Sung Lee, R. Taylor Ripley, Todd Rosengart, Hu Ying Shen, Sarah Woodfield, Ketti Eipers-Smith and Kimberly Holloway.

#NHI #MedicalResearch #HowTo #Grant #ResearchPlan

[The Journal of Immunology @J_Immunol]

A #TopRead article from Dr. Jesse Bruijnesteijn found that a diverse repertoire of killer cell immunoglobulin-like receptors (KIRs) contributes to the protection of individuals and populations against pathogen evasion and subversion. Read it in The JI: https://t.co/uO3IkyZQYq

[Waggoner Lab @LabWaggoner]

The innate power of NK cells in cancer therapy
@MalmbergLab @NatureMedicine
on @lab_rezvani trial
https://t.co/1infXSaiEd

[Yakup Ergün @dr_yakupergun]

TNM classification 9ᵗʰ edition

T stage

https://t.co/yA7h7sgLYH

[Nature Reviews Drug Discovery @NatRevDrugDisc]

For readers interested in approaches to reset the immune system to treat autoimmune diseases, here's a comprehensive review https://t.co/oYPCyIOa8c
https://t.co/P0NxIsUzKc

[From the Labs at Baylor College of Medicine @BCMFromtheLabs]

Check out the new paper by HS Lee, @BMBurtMD, @ShandaBlackmon et al about a prognosticator in pleural #mesothelioma. @BCM_Surgery @bcmhouston

[Eric Topol @EricTopol]

New evidence today @NEJM that age-related clonal hematopoiesis (CHIP) has a driver role in evolution of solid cancers
https://t.co/J8zAskV32l
https://t.co/3uvAc03p8K

[Immunity @ImmunityCP]

Online now: Soluble CTLA-4 regulates immune homeostasis and promotes resolution of inflammation by suppressing type 1 but allowing type 2 immunity https://t.co/gznSAhnyQE

[Cell Press @CellPressNews]

"CDK4 selective inhibition improves preclinical antitumor efficacy and safety" https://t.co/NfkdnoE8uD

@pfizer Lars Anders
@Cancer_Cell